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Abstract: To facilitate the temporary importation of horses for competition and racing purposes, 
with a minimum risk of transmitting equine influenza, the World Organisation for Animal Health 
(Office International des Epizooties, or OIE), formally engaged in a public–private partnership with 
the Federation Equestre Internationale (FEI) and the International Federation for Horseracing 
Authorities (IFHA) to establish, within the context of existing OIE standards, a science-based 
rationale to identify the ideal time period for equine influenza vaccination prior to shipment. Field 
trials using vaccines based on different technologies were carried out on three continents. The 
antibody response post-booster vaccination at intervals aligned with the different 
rules/recommendations of the OIE, FEI, and IFHA, was monitored by single radial haemolysis. It 
was determined that 14 days was the optimum period necessary to allow horses adequate time to 
respond to booster vaccination and for horses that have previously received four or more doses of 
vaccine and are older than four years, it is adequate to allow vaccination within 180 days of 
shipment. In contrast, the results indicate that there is a potential benefit to younger (four years old 
or younger) horses in requiring booster vaccination within 90 days of shipment, consistent with the 
current OIE standard. 
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1. Introduction 
Equine influenza (H3N8) viruses are highly contagious, particularly in immunologically naïve 
populations [1]. The first incursion in Australia resulted in the infection of approximately 75,000 
horses on 9,400 premises in New South Wales and Queensland, and at the very early stage of the 
epidemic up to 98 premises became infected through the movement of horses from two equestrian 
competition events [2,3]. The economic losses to the equine industry, in addition to the 
implementation of an immediate national standstill of horses followed by risk-based movement 
controls, laboratory testing, strategic vaccination of over 136,000 horses, and other measures that 
contributed to an effective eradication programme, are estimated to have cost billions of dollars [4]. 
Similar equine influenza virus incursions in Hong Kong [5], Japan [6], South Africa [7,8], Turkey [9], 
Malaysia [10] and other countries have also resulted in economic loss, due to movement restrictions 
and cancellation of equestrian events. More recently, in 2018 and 2019, widespread outbreaks in 
South America [11] and Africa affected thousands of horses and donkeys, respectively [12]. In 2019, 
many European countries experienced an increase in equine influenza activity [13], and in the United 
Kingdom horse racing was cancelled for six days, with media reports of revenue loss in excess of £100 
million.  
In a systematic review by Dominguez et al. [14], equine influenza was identified as the equine 
pathogen most frequently responsible for disease events post-importation. The international spread 
of equine influenza is frequently associated with the movement of horses from endemic areas, such 
as Europe and North America [5,7–9,15]. The Australian outbreak appears to have been introduced 
by thoroughbred horses from Japan, the virus having recently arrived there from the United States 
[16]. The majority of importing countries require that horses are vaccinated against equine influenza, 
and sporting bodies implement mandatory vaccination policies to minimise disruption to equestrian 
events. However, the vaccines do not afford sterile immunity, and virus incursions are frequently 
associated with the importation of subclinically infected vaccinated horses [5–8,16,17]. In order to 
decrease this risk, it is essential that the vaccination policies implemented are science-based and 
targeted towards minimising virus shedding. 
To facilitate the temporary importation of horses for competition and racing purposes, with a 
minimum risk of transmitting infectious diseases like equine influenza, the World Organisation for 
Animal Health (Office International des Epizooties, or OIE) formally engaged in a public–private 
partnership with the Federation Equestre Internationale (FEI) and the International Federation for 
Horseracing Authorities (IFHA). The main aim of this initiative was to establish, within the context 
of the existing OIE standards, new standards and guidelines relating to infectious diseases, such as 
equine influenza. According to the FEI veterinary rules and the IFHA guidelines, competing horses 
must be vaccinated against equine influenza, but their recommendations are not harmonized and not 
in line with OIE standards, as documented in the Terrestrial Animal Health Code [18]. As industry 
partners, the FEI and IFHA provided support to the OIE to conduct this project, the aim of which was 
to provide a science-based rationale for identifying the ideal time period for equine influenza 
vaccination prior to shipment. Two international field trials were carried out, using vaccines based 
on different technologies. The aim of the first trial was to determine the mandatory interval between 
booster vaccination and shipment necessary to allow the horse adequate time to respond to booster 
vaccination. The aim of the second trial was to determine the durability of the antibody response 
induced by booster vaccination, and therefore the appropriate maximum interval between booster 
vaccination and shipment. 
2. Materials and Methods 
2.1. Study Design 
Table 1 summarises the FEI, IFHA, and OIE recommendations for vaccination prior to export or 
competition. In an effort to harmonise these recommendations, two international field trials were 
conducted. The focus of Trial A was to determine the time necessary for the horses to respond to 
booster vaccination, i.e., how close to shipment they could be vaccinated. Thus, horses received their 
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booster vaccination in accordance with their usual vaccination schedule, and their response was 
monitored at 7 days (FEI), 14 days (IFHA), and 21 days (OIE) post-booster. The focus of Trial B was 
to determine how long before shipment horses could be vaccinated and maintain a high level of 
antibodies at the time of shipment. Thus, horses received their booster vaccination in accordance with 
their usual vaccination schedule, and their response was monitored at 60 days (IFHA), 90 days (OIE), 
and 180 days (FEI) post-booster. In both trials, the response to vaccination was monitored using the 
single radial haemolysis (SRH) test, as the correlation between SRH antibodies and protection against 
infection (virological protection) and disease (clinical protection) is well established [19–21]. 
Table 1. Recommendations for equine influenza vaccination. 
Recommendation FEI 1 IFHA 2 OIE 3 
Boost before 
export/competition  
For horses competing, the last 
booster must be given within 6 
months + 21 days (and not 
within 7 days) before arrival at 
the event 
During the 60 days 
immediately prior to export 
from its country of origin, 
but not within 14 days of 
export. 
Immunised 
between 21 and 90 
days before 
shipment 
1 Federation Equestre Internationale. 2 International Federation for Horseracing Authorities. 3 World 
Organisation for Animal Health (Office International des Epizooties). 
2.2. Horses 
The selection of horses was at the discretion of the participating countries that volunteered to 
assist with either or both trials in the target population, i.e., racehorses or sport horses. Experimental 
animals were not eligible for inclusion. In all countries, the horses recruited to the study were due 
their booster vaccination as part of routine preventative health measures, and in accordance with the 
regulations of the relevant authorities. The attending veterinary surgeon administered the customary 
vaccine, collected the blood samples, and monitored the health status of the horses in their care 
throughout the study period. The inclusion of the horses in the trials was dependent on the good will 
and cooperation of the horse owners/managers, the veterinary surgeons and the support staff. 
Germany performed studies for both Trials A and B in the same group of horses, Argentina and Japan 
performed three studies (two for Trial A and one for Trial B in Argentina; two for Trial B and one for 
Trial A in Japan) in different groups of horses, and Singapore opted to perform one study for Trial B. 
In each country, participation in the study (AD/SR/2015/1885 2.3.) was approved by the appropriate 
institutional review board. 
Of the 194 horses recruited for Trial A, 103 were in Germany, 64 were in Argentina and 27 were 
in Japan. In Germany, the horses were young sport horses ranging in age from two to seven years 
old (median: three years). They received a dose of vaccine approximately six months prior to the 
study. They received a total of 5 to 16 (mean = 7.5 ± 2.2) doses of vaccine. In Japan, the horses were 
sport horses ranging in age from 6 to 20 (median: 13 years), and they had been vaccinated six months 
prior to the study. While under the care of the Japanese Racing Association (JRA), the horses received 
at least 4 to 40 doses of vaccine (mean = 18.7 ± 9.5) in approximately six monthly intervals. No 
vaccination history was available prior to JRA ownership. In Argentina, 30 sport horses ranged in 
age from 4 to 17 (median: eight years), and 30 of 34 racehorses ranged in age from three to five 
(median: three years). The age of the remaining four racehorses was not available. Individual 
vaccination histories were not available for the Argentine horses, but it is mandatory in Argentina 
that both racehorses and sport horses are vaccinated four times a year. The horses recruited to the 
study had received a dose of vaccine three months prior to the study. 
Of the 226 horses recruited for Trial B, 79 were in Germany, 33 were in Argentina, 74 were in 
Japan and 40 were in Singapore. In Germany, the horses were young sport horses ranging in age from 
two to seven years old (median: four years). They had received a dose of vaccine approximately six 
months prior to the study. They received a total of 5 to 16 (mean = 7.9 ± 2.2) doses of vaccine. In Japan, 
43 three-year-old racehorses and 31 sport horses ranging in age from 6 to 20 (median: 13 years) were 
recruited to the study. Both groups had received a dose of vaccine approximately six months prior to 
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the study. The racehorses received a total of six doses of vaccine, and the sport horses received at 
least 4 to 40 doses of vaccine (mean = 19.2 ± 9.2). There were no vaccination records available prior to 
JRA ownership; thus, the numbers cited may be an underestimation of the vaccines received. In 
Argentina, 33 sport horses ranged in age from 4 to 21 (median: 11 years). They received a total of 4 to 
26 (mean = 13.3 ± 6.5) doses of vaccine, and had received their last vaccine three months prior to the 
study. In Singapore, 40 racehorses ranged  in age from 4 to 12 (median: five years). Vaccination 
records for 28 of these horses indicated that they received a total of 2 to 19 (mean = 5.8 ± 3.8) doses of 
vaccine, and had received their last vaccine six months prior to the study. 
2.3. Vaccines 
For Trial A in Germany, the horses were randomly allocated one of three vaccines, 34 were 
vaccinated with a subunit vaccine—namely, Equip FT (Zoetis, Parsippany-Troy Hills, NJ, United 
States), 34 with the canary pox recombinant vaccine ProteqFlu TE (Merial S.A.S./Boehringer 
Ingelheim,29 Avenue Tony Garnier, 69007, Lyon, France), and 35 with the whole inactivated virus 
vaccine Duvaxyn IE T Plus (Elanco Animal Health, Eli Lilly Ltd., Priestly Road, Basingstoke, RG24 
9NL, United Kingdom). In Japan, the 27 horses were vaccinated with a nationally produced, whole 
inactivated vaccine (Nisseiken, Shin-machi, Ome, Tokyo 198-0024, Japan). In Argentina, 34 racehorses 
were vaccinated with the inactivated vaccine Fluvac Innovator (Zoetis), and 30 sport horses were 
vaccinated with the nationally produced, inactivated vaccine INFLUQIM (Biochemiq, Del Cañon 
2690, Moreno,  Buenos Aires, Argentina). 
For Trial B, the horses in Germany had been included in Trial A, and thus 26 had been vaccinated 
with a subunit vaccine—namely Equip FT (Zoetis), 23 with the canary pox recombinant vaccine 
ProteqFlu TE (Boehringer Ingelheim/Merial), and 30 with the whole inactivated virus vaccine 
Duvaxyn IE T Plus (Elanco). In Japan, all horses were vaccinated with a whole inactivated Japanese 
vaccine (Nisseiken). In Argentina, all horses were vaccinated with the inactivated vaccine Fluvac 
Innovator (Zoetis), and in Singapore the horses were vaccinated with the recombinant vaccine 
ProteqFlu TE (Boehringer Ingelheim/Merial). 
2.4. Sample Collection 
For Trial A, clotted blood samples were collected on the day of vaccination, as well as 7, 14, and 
21 days post-vaccination. These sampling days were aligned with the rules and recommendations of 
the FEI (7 days), IFHA (14 days), and OIE (21 days). 
For Trial B, clotted blood samples were collected on the day of vaccination and day 21 
(Germany), day 30 (Japan, Argentina, Singapore), days 60 and 90 (Germany, Japan, Argentina, 
Singapore), and day 180 post-vaccination (Germany, Japan, Argentina). The sampling days of 60, 90, 
and 180 were aligned with the rules and recommendations of the IFHA (60 days), FEI (6 months +21 
days grace period), and OIE (90 days). 
As these were field trials conducted in the target population, some of the horses could not be 
sampled at one or more of the sampling times for operational reasons, or they were lost to the study  
because they were sold or removed from the premises. In Germany, the same horses were used for 
Trial A and Trial B. In order to reduce labor and animal handling, it was agreed that the sample 
collected at 21 days for Trial A could also serve to monitor the response to vaccination for Trial B, the 
aim of which was to compare the antibody levels at three time points, i.e., days 60, 90, and 180 days 
post-vaccination. 
2.5. Serology 
Antibodies against two H3N8 viruses--A/equine/Meath/2007, a representative of Clade 2 of the 
Florida sublineage, and A/equine/South Africa/4/2003, a representative of Clade 1 of the Florida 
sublineage—were measured using the SRH test, as previously described [22]. The area of haemolysis 
resulting from the lysis of equine influenza antigen-coated sheep red blood cells by the antibody in 
the test sera were expressed in mm2. Mean H3N8 antibody values were calculated from SRH results 
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obtained, and seroconversion was defined as an increase in antibody level of ≥25 mm2 [23]. Similarly, 
a significant decline in antibody titre was defined as a decrease of ≥25 mm2. The laboratory 
investigator was blind to vaccine allocation to individual horses. 
2.6. Statistical Analysis 
All statistical analysis was carried out on the base distribution of the open-source package R 
version 3.1.1 [24], with no additional specific packages used. The R code used for analyses is available 
from the authors on request. A significance level of p < 0.05 was used for all statistical tests. 
Throughout the report, where there were missing values, the analysis was carried out using case-
wise deletion. A case-wise deletion strategy was used in order to ensure the values at each timepoint 
were based on the same cohort of animals; the reason for missing observations is discussed in the 
section on sample collection above. Plots and analyses contain >150 horses unless otherwise specified. 
When comparing changes in titre between timepoints, pairwise t-tests were used. In examining the 
association of multiple covariates with the response to vaccination and subsequent waning, a 
multivariate linear model was fitted, with backwards stepwise elimination where appropriate. In 
these multivariate analyses, models were fitted to summarise the impact of vaccination on the change 
in titre from the baseline in different animals. The variables entered into the model included age, 
vaccine type, and number of previous vaccinations. Separate models were fitted, including age and 
number of previous vaccinations, because of confounding between these variables, as discussed 
below. 
3. Results 
In accordance with previously established correlates of the protection SRH titres >150 mm2 were 
interpreted as consistent with virological protection, and titres >85 mm2 but <150 mm2 were 
interpreted as consistent with clinical protection against antigenically closely related (homologous) 
strains [19–21]. SRH titres >165 mm2 were interpreted as consistent with virological protection against 
heterologous strains [25]. An increase in antibody level of ≥25 mm2 was interpreted as a 
seroconversion [23]. The SRH results for both trials are presented in the Supplementary Data files, in 
Table S1 (Trial A) and Table S2 (Trial B). 
3.1. Trial A 
The SRH antibody titre of all horses was measured at the time of booster vaccination and 7, 14, 
and 21 days post-vaccination. There was a significant increase in SRH titre between the day of the 
booster vaccination and day 7 post-vaccination (p < 0.001), as well as between day 7 and day 14 post-
vaccination (p < 0.001). There was no significant difference in SRH titre between day 14 and day 21 
post vaccination (p = 0.43). Ninety-four horses seroconverted between the day of booster vaccination 
and day 7 post-vaccination, and 49 seroconverted between day 7 and day 14 post-vaccination, but 25 
of those had already seroconverted by day 7 (i.e., their titres were continuing to rise). Five horses 
with SRH titres >143 mm2 experienced a significant rise in antibody level between day 14 and day 21 
post-vaccination. These results are summarised in Figure 1. 
Multivariate analysis demonstrated that age, number of vaccines received and vaccine type all 
had a significant (p < 0.001) impact on the response to booster vaccination. The response to the canary 
pox recombinant vaccine was delayed when compared to that of the response to the subunit or whole 
inactivated vaccines. None of the horses vaccinated with the recombinant vaccine seroconverted 
between day 0 and day 7. The horses that seroconverted during the first week post-booster 
vaccination were all vaccinated with whole inactivated or subunit vaccines. Twenty two of the 24 
horses that initially seroconverted between day 7 and 14 were vaccinated with the recombinant 
vaccine. The five horses that seroconverted between days 14 and 21 post-vaccination all received the 
recombinant vaccine. However, three of these had already seroconverted to the vaccine by day 14—
i.e., their titres continued to rise between days 14 and 21. The impact of vaccine type on the response 
to vaccination is illustrated in Figure 2a–c. 
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Figure 1. Number of horses with an increase in single radial haemolysis (SRH) titre of ≥25 mm2 
between the day of booster vaccination (day 0) and day 7 post-vaccination, between day 7 and day 14 
post-vaccination, and between day 14 and 21 post-vaccination. 
 
(a) 
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(c)  
Figure 2. The impact of vaccine type on the response to vaccination. The change in SRH antibody 
titres between days 0 and 7 (n = 192), days 0 and 14 (n = 188), and days 14 and 21 (n = 182) by age is 
represented in (a–c), respectively. The black circles represent the horses vaccinated with a 
recombinant vaccine (R), the red circles represent the horses vaccinated with a subunit vaccine (S), 
and the green circles represent horses vaccinated with whole inactivated vaccine (W). The red 
horizontal line is drawn at 25 mm2, as a rise of ≥25 mm2 is considered significant (i.e., a 
seroconversion). 
As the age of the horse increased, the antibody response to booster vaccination decreased (Figure 
2a–c). However, age and number of vaccinations are confounded. This is illustrated in Figure 3, where 
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clearly the majority of horses over four years of age had received more than 10 doses of vaccine and 
failed to seroconvert to booster vaccination. Only three horses that had received more than 10 doses 
of vaccine seroconverted in response to booster vaccination. These were one 6-year-old and two 7-
year-olds. 
 
Figure 3. The change in SRH antibody titres between days 0 and 14 (n = 123) by age is represented 
with a red horizontal line drawn at 25 mm2, as an increase of ≥ 25 mm2 is considered significant (i.e., 
a seroconversion). The black circles represent the horses that received >10 doses of vaccine, the red 
circles represent the horses that received <10 but >5 doses of vaccine, the green circles represent horses 
that received five doses of vaccine, and the blue circles represent horses that received four doses of 
vaccine. The Argentine horses were not included in the graph, as individual vaccination histories 
were not available. The number of vaccinations for the Japanese horses illustrated on the graph 
represent those recorded by the Japanese Racing Association (JRA). Vaccination history prior to JRA 
ownership was not available; thus, four Japanese horses that did not seroconvert and are represented 
on the graph as having received <10 doses of vaccine may have actually received more than the 
number of doses recorded. 
At time of vaccination, the majority of the horses (74%) with SRH titres >150 mm2 were more 
than four years of age. The majority of horses (75%) with SRH titres >85 mm2 and <150 mm2 were four 
years old or younger. Ninety-one percent of the horses with SRH titres <85 mm2 were four years old 
or younger. Fourteen days post-booster vaccination, 67% of horses had SRH titres >150 mm2 and only 
three racehorses (aged three and four years, and one unknown) were below 85 mm2. Figure 4 
illustrates the SRH titres at time of vaccination (4a) and after vaccination (4b). 
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(b) 
Figure 4. Both Figure 4a,b represent the change in SRH antibody titres between days 0 and 14 (n = 
188) by age. The red horizontal line is drawn at 25 mm2, as an increase of ≥25 mm2 is considered 
significant (i.e., a seroconversion). The figures differ in that (a) indicates the titres for the individual 
horses on day 0, and (b) indicates the titres for the same horses on day 14 post-vaccination. The empty 
circles represent horses with SRH titres <85 mm2, the filled circles represent horses with SRH titres 
>85 mm2 but <150 mm2,and the crosses represent horses with SRH titres >150 mm2. 
Vaccines 2020, 8, 107 10 of 18 
 
3.2. Trial B 
There was a significant increase in SRH titre between the day of booster vaccination and day 21 
(German horses only) or 30 post-vaccination (p < 0.001), and significant decrease between days 21/30 
and 60, days 60 and 90, and days 90 and 180 post vaccination (p < 0.001). 
One hundred and thirty-one of 218 horses (60%) seroconverted between the day of booster 
vaccination and day 21/30 post vaccination. Between days 21/30 and 60, days 60 and 90, and days 90 
and 180 post-vaccination 65, 19, and 24 horses respectively, experienced a decrease in SRH titre of 
≥25 mm2 (see Figure 5a). This is equal to 31% (210 paired samples), 9% (216 paired samples), and 15% 
(160 paired samples) of the horses tested at 60, 90, and 180 days post-vaccination, respectively. At 
least 13 of the 19 and 16 of the 24 horses that experienced a significant decrease in SRH titre between 
days 60 and 90 and days 90 and 180 post-vaccination respectively, had already experienced a 
significant decline at a previous time point. 
On the day of vaccination, the horses four years old or younger had significantly lower antibody 
levels than the horses older than four years of age (p = 0.003), but they responded very well to 
vaccination—83% seroconverted by day 21/30. Of the 131 horses that seroconverted post-booster 
vaccination, 99 were four years of age or younger. At 30 days post-vaccination, the horses four years 
of age or younger had SRH levels higher than those of the older horses (p < 0.001), but it was primarily 
the young horses that experienced a decline in antibody level by 60, 90, and 180 days post vaccination 
(see Figure 5a,b). 
 
(a) 
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Figure 5. (a) The decline in SRH antibody level ≥25 mm2 experienced by horses four years old or 
younger and those over four years old between days 21/30 and 60, days 60 and 90, and days 90 and 
180 post-booster vaccination. (b) The mean SRH antibody levels for 150 horses (four years old or 
younger (red), n = 96; over four years old (blue), n = 54) with a complete set of samples for days 0, 21 
(German horses only) or 30 (this sampling is represented on the horizontal axis of the graph as Day 
30), 60, 90, and 180. 
Multivariate analysis demonstrated that age and the number of vaccines received previously 
were negatively associated with the initial response to vaccination at days 21/30, but positively 
associated with the SRH titre at each subsequent time point (p < 0.001). However, age and number of 
vaccines are confounded, as the older horses have received more vaccine doses (Figure 6a,b). 
 
(a) 
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(b) 
Figure 6. The change in SRH antibody titres between days 60 and 90 (n = 216) and days 90 and 180 (n 
= 160) by age is represented in (a) and (b), respectively. The black circles represent the horses that 
received >10 doses of vaccine, the red circles represent the horses that received <10 but >5 doses of 
vaccine, the green circles represent horses that received five doses of vaccine, and the blue circles 
represent horses that received four doses of vaccine. The red horizontal line is drawn at −25 mm2, as 
a decrease of ≥25 mm2 is considered significant. 
The analysis of the effect of time since last vaccination was confounded by the data set; with the 
exception of the Argentine horses, all horses had been vaccinated approximately six months prior. 
The analysis of the impact of vaccine type was confounded by age, as only the younger horses 
received the subunit and recombinant vaccines. However, Figure 7 clearly illustrates that young 
horses experience a decline in antibody levels between day 60 and day 180 post-booster vaccination 
irrespective of the type of vaccine used. 
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Figure 7. The change in SRH antibody titres between days 60 and 180. The black circles represent the 
horses vaccinated with the recombinant vaccine (R) , the red circles represent the horses vaccinated 
with the subunit vaccine (S), and the green circles represent horses vaccinated with the whole 
inactivated vaccine (W). The red horizontal line is drawn at −25 mm2, as a decrease of ≥ 25 mm2 is 
considered significant. 
SRH antibodies above 165 mm2i.e., levels that are considered consistent with virological 
protection against heterologous strains [25] are not always achieved by repeated vaccination. By day 
180, only 18 of 162 horses had SRH levels above 165 mm2. However, despite the decline in antibody 
levels of the younger horses at day 180, there were only 12 of 162 horses in the study at that time 
point that had antibody levels <85 mm2, which is considered to be the threshold of clinical protection 
[19–21]. Of these, eight were three years old, and the remaining four consisted of a 2-, 4-, 7-, and 16-
year-old. When their SRH levels at 60, 90, and 180 days post-vaccination were compared, only two of 
the 12 had significantly better (i.e., ≥25 mm2) levels on day 60 or 90 post-vaccination than they had on 
day 180. Thus, it appears that for the majority of horses that respond poorly to vaccination, shortening 
the vaccination interval prior to shipment is of little benefit. 
4. Discussion 
International travel is essential to the sustainability of the horse industry, and horses move 
between countries for breeding, sales, exhibitions, and competitions. Horses travel more by air than 
any other species except man, and air transport appears to increase the susceptibility of the 
respiratory tract to viral infections, such as influenza [26–28]. This study was implemented through 
a public private partnership of the OIE, FEI, and IFHA, with the aim of developing an evidence-based 
vaccination strategy to decrease the risk of travel-based equine influenza outbreaks. The inclusion of 
both racehorses and competition horses in the study ensured representation of different sectors of 
the industry, and the international framework, with participants in three continents, was designed to 
promote global engagement of stakeholders. Furthermore, vaccines from multinational companies 
and national companies were included, as were both traditional and second-generation vaccines. 
With the exception of the Argentine horses, the horses had received their last dose of vaccine 
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approximately six months prior to the study. In accordance with national regulations, the Argentine 
horses had been vaccinated three months prior to booster vaccination. However, there was no 
evidence that the time since last vaccination confounded the results, as analysis excluding the 
Argentine animals from both trials resulted in the same findings. 
Vaccine hesitancy, a term that encompasses refusal to vaccinate, delaying vaccination, and lack 
of confidence, has been identified by the World Health Organisation as one of the top ten global 
health threats of 2019 [29]. It is important to recognise the spillover of opposition to mandatory 
vaccination from human to animal health, as horse owners and trainers are concerned about the 
adverse effects of repeated vaccination [30,31]. Vaccination is one of the most effective means of 
avoiding equine influenza virus transmission, but in order to retain the confidence of the industry, it 
is imperative that vaccination regulations are science-based, and desirable that they be harmonised 
internationally. Currently the OIE, FEI, and IFHA recommendations for vaccination boost before 
export or competition are not harmonised. The OIE standard is that horses are immunised between 
21 and 90 days before shipment. The IFHA recommends that horses are vaccinated during the 60 
days immediately prior to export from their country of origin, but not within 14 days of export. For 
horses competing in FEI events, the last booster must have been given within 6 months and 21 days 
(and not within 7 days) before arrival at the event. Thus the focus of this investigation was to provide 
a science-based rationale for which of the intervals used (i.e., 7 days, 14 days, or 21 days) allows 
horses adequate time to respond to booster vaccination, and whether the immune response elicited 
is sustainable for 60 days, 90 days, or 6 months (180 days). 
The response to booster vaccination in this study was monitored serologically. The induction of 
a cellular immune response has been demonstrated for the three most widely available types of 
equine influenza vaccines—whole inactivated, subunit, and canary pox recombinant—all of which 
were included in the study, but has not yet led to the development of correlates of protection [32–35]. 
In contrast, antibodies against the equine influenza haemagglutinin neutralise the virus, and can be 
measured by SRH or by haemagglutination inhibition. However, only SRH is internationally 
standardised [36,37], and is currently the method of choice for the assessment of vaccinal immunity 
dynamics with a view to optimising vaccination regimes. The correlation between SRH antibodies 
and protection has been observed in experimental challenge studies [38–40] and in the field during 
outbreak investigations [23,25,41]. Antibody levels between 85 mm2 and 150 mm2, as determined by 
SRH, are internationally accepted as the protection threshold for clinical protection and antibody 
levels > 150 mm2 for virological protection, when the challenge virus is antigenically closely related 
to the virus in the vaccine [19–21]. However, strain-specific antibodies against influenza are more 
effective than  cross-reactive antibodies [42,43]. Higher antibody levels are required for protection 
when there is a mismatch between the vaccine strain and the field circulating strain [41,44]. In 1987 
in South Africa, where the population had no natural immunity, pre-challenge vaccine-induced SRH 
levels of >165 mm2 correlated with 90% protection against infection, as indicated by seroconversion 
[25]. The strains in the vaccines were not homologous to the strain that caused the outbreak in South 
Africa, but all of them induced protective cross-reacting antibodies. Thus, notwithstanding the 
complexities of strain heterogeneity, the SRH is considered to be the gold standard for the assessment 
of vaccine efficacy in the absence of virus challenge studies. Although many horses fail to achieve or 
to maintain virological protection, maximizing their level of neutralizing antibodies decreases virus 
shedding and reduces the risk of travel-based equine influenza outbreaks. 
At the time of commencement of Trial A, the horses had a mean SRH antibody level of 116 mm2, 
and by day 14 post-vaccination the mean had risen to 168 mm2. These SRH results are very similar to 
those observed in a previous study of response to booster vaccination in regularly vaccinated 
National Hunt racehorses [45]. Trial A focused on comparing the humoral response at 7, 14, and 21 
days post-vaccination, and the results suggest that 14 days is the optimum period to allow for horses 
to respond to vaccination prior to shipment. Seven days is not ideal, as not all horses seroconvert 
within seven days. In particular, and consistent with a previous comparative vaccine study [45], the 
response to booster vaccination with the recombinant vaccine was later than the peak antibody 
response to booster vaccination with the subunit or whole inactivated vaccines. It is important to 
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allow time to respond to the recombinant vaccine, as it is currently one of the vaccines that contains 
the viruses recommended by the OIE Furthermore, the antibody response to the recombinant vaccine 
allows for differentiation of infected from vaccinated animals DIVA,  [46,47]. The benefit of waiting 
for 21 days rather than 14 was not significant, as 98% of the horses that seroconverted had done so 
within 14 days. 
Trial B focused on the decrease in antibodies 60, 90, and 180 days post-vaccination, as these were 
the candidate vaccination intervals for international standardisation. The kinetics of the antibody 
response differed depending on the age of the horse. This was confounded with the vaccination 
history, as older horses have received more vaccine doses. Young horses responded better to booster 
vaccination, but thereafter their antibodies were not as persistent as those of the older horses. The 
mean SRH antibody level for the 96 horses four years old or younger, with a complete data set, was 
141 mm2 at day 60, 131 mm2 at day 90, and 117 mm2 at day 180. The mean SRH antibody level for 54 
horses over four years of age was 147 mm2 at day 60, 148 mm2 at day 90, and 141 mm2 at day 180. 
Thus, the results of the studies in Trial B suggest that for horses that have received four or more doses 
of vaccine, and are older than four years, there is little benefit in requiring a booster vaccination 
within 60 or 90 days prior to shipment rather than within 180 days, as their antibody levels are 
relatively stable. In contrast, the results indicate that there is a potential benefit to younger (four years 
old or younger) horses in requiring booster vaccination closer to shipment. Eight of the 96 young 
horses experienced a decline of ≥25 mm2 between days 60 and 90, but this rose to 21 between days 90 
and 180. Within 90 days prior to shipment is consistent with the current OIE standard. A 
recommendation of vaccination within 90 days prior to shipment for horses four years old or younger 
would result in higher antibody levels than a recommendation for vaccination within 180 days prior 
to shipment. This study did not include full data sets from horses that had received fewer than four 
doses of vaccine, and as previous studies provided evidence of poor antibody persistence after initial 
vaccinations, it would be prudent to include such horses, irrespective of their age, in the 
recommendation for vaccination within 90 days prior to shipment [48]. 
International horse movement is under the control of national veterinary authorities, not 
equestrian authorities. The majority of countries that insist on vaccination against equine influenza 
require that the horse receives a vaccine between 14 and 90 days before shipment. Equipped with the 
information derived from this study, importing countries can gain insight into different vaccination 
strategies, taking account of the time required to respond to different types of vaccines and the 
persistence of vaccine-induced antibodies with increasing age. This in turn will hopefully contribute 
to a harmonised approach in line with revised OIE guidelines. 
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